GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for REWIND

REWIND

Official Title

The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)

Status

Ongoing

Overview

To assess the effect of once-weekly 1.5mg LY2189265 on CV outcomes when added to the existing antihyperglycemic regimen of patients with type-2 diabetes. Data not being collected by PHRI.

Study Design

Randomized, double-blind, placebo controlled parallel study to assess the effect of once-weekly 1.5mg LY2189265 on CV outcomes when added to the existing antihyperglycemic regimen of patients with type-2 diabetes.

Primary Endpoint

The composite primary endpoints are death from CV causes, nonfatal myocardial infarction (MI), or nonfatal stroke.

Number of Patients

9903

Number of Sites

404

Number of Countries

24

Study Period

2011–2019

Principal Investigator

Hertzel Gerstein

Program Manager

Jackie Bosch

Research Coordinator

Stephanie Hall

Collaborators

Eli Lilly